

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)

	2019						2020						\$ Change		% Change			
	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr ^(b)	Year ^(b)	1st Qtr ^(c)	2nd Qtr ^(c)	6 Months ^(c)	3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
Prioritized Brands																		
Revlimid	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 1,299	\$ 1,299	\$ 2,915	\$ 2,884	\$ 5,799					\$ 2,884	\$ 5,799	N/A	N/A
Eliquis	1,925	2,042	3,967	1,928	5,895	2,034	7,929	2,641	2,163	4,804					121	837	6%	21%
Opdivo	1,801	1,823	3,624	1,817	5,441	1,763	7,204	1,766	1,653	3,419					(170)	(205)	(9)%	(6)%
Orencia	640	778	1,418	767	2,185	792	2,977	714	750	1,464					(28)	46	(4)%	3%
Pomalyst/Imnovid	—	—	—	—	—	322	322	713	745	1,458					745	1,458	N/A	N/A
Sprycel	459	544	1,003	558	1,561	549	2,110	521	511	1,032					(33)	29	(6)%	3%
Yervoy	384	367	751	353	1,104	385	1,489	396	369	765					2	14	1%	2%
Abraxane	—	—	—	—	—	166	166	300	308	608					308	608	N/A	N/A
Empliciti	83	91	174	89	263	94	357	97	97	194					6	20	7%	11%
Reblozyl	—	—	—	—	—	—	—	8	55	63					55	63	N/A	N/A
Inrebic	—	—	—	—	—	5	5	12	15	27					15	27	N/A	N/A
Zeposia	—	—	—	—	—	—	—	—	1	1					1	1	N/A	N/A
Established Brands																		
Baraclude	141	147	288	145	433	122	555	122	121	243					(26)	(45)	(18)%	(16)%
Vidaza	—	—	—	—	—	58	58	158	126	284					126	284	N/A	N/A
Other Brands ^(a)	487	481	968	350	1,318	356	1,674	418	331	749					(150)	(219)	(31)%	(23)%
Total	\$ 5,920	\$ 6,273	\$ 12,193	\$ 6,007	\$ 18,200	\$ 7,945	\$ 26,145	\$ 10,781	\$ 10,129	\$ 20,910					\$ 3,856	\$ 8,717	61%	71%

(a) Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue. Other Brands includes \$83 million and \$205 million relating to Celgene products in the three and six months ended June 30, 2020, respectively.

(b) Includes Celgene product revenues from November 20, 2019 through December 31, 2019.

(c) Includes Celgene product revenues for the entire period.